Brief: Editas Medicine Inc - Nominates Edit-401 As Lead In Vivo Candidate
02/09/2025 13:28
Editas Medicine Inc EDIT.O: EDITAS MEDICINE INC - NOMINATES EDIT-401 AS LEAD IN VIVO CANDIDATE EDITAS MEDICINE INC - EDIT-401 ON TRACK FOR HUMAN PROOF-OF-CONCEPT DATA BY END OF 2026 EDITAS MEDICINE INC - TO SUBMIT IND OR CTA FOR EDIT-401 BY MID-2026 Source text: ID:nGNX71kqvq Further company coverage: EDIT.O
Recent news on Editas Medicine
See all newsEditas Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview
Editas Medicine Q2 net loss narrows and beats estimates
Brief: Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million
Editas Medicine down after $125 mln stock-and-warrants offering